BioMarin-JPM-20240108.pdf

《BioMarin-JPM-20240108.pdf》由会员分享，可在线阅读，更多相关《BioMarin-JPM-20240108.pdf（16页珍藏版）》请在三个皮匠报告上搜索。

1、BioMarin Pharmaceutical Inc.Alexander HardyPresident and Chief Executive OfficerJanuary 8,202442nd Annual J.P.Morgan Healthcare Conference 2 23 3My Background and Relevant ExperienceWhy I Chose BioMarinKey Priorities Ahead1234 4Track record of innovation,accelerating new product growth and deliverin

2、g operational efficienciesFormer CEO of Genentech($25 billion in revenue and 13,500 employees)with over 30 years of industry experience across global pharma industry and biotechnologyA bit about me.Implemented operating model with novel ecosystem approach and emphasis on omnichannel to drive superio

3、r customer experience and greater flexibilityDelivered accelerating revenue growth,leveraged to the bottom-lineOperational ExcellenceIn last 5 years,launched 10 new medicines Returned company to strong growth following 3 simultaneous LOE events(40%of revenue)and attained/sustained leadership positio

4、ns in highly competitive markets Commercial ExcellenceResponsible for Global Product StrategyLed late-stage strategy,launch and LCM across oncology,benign hematology,neuroscience,immunology and ophthalmologyLifecycle Management Experience5Industry-leading Innovation throughProven R&D Engine100%comme

5、rcialization rate for Phase 3 assets;8 internally developed commercial products50%Investigational New Drug(IND)to marketing authorization approval rateMulti-modal expertise,global regulatory capabilities and wholly-owned manufacturing Strong Revenue Growth Potential Significant multi-year growth dri

6、ver with VOXZOGOin achondroplasia and new indicationsROCTAVIANfor severe hemophilia A as a potential standard of care gene therapyDurable,profitable,“IRA-insulated”annuity-like base businessSignificant Profitability Opportunities8 approved products driving industry-leading revenue growth Financially